Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

M.J. van den Bent*, C.M.S. Tesileanu, W. Wick, M. Sanson, A.A. Brandes, P.M. Clement, S. Erridge, M.A. Vogelbaum, A.K. Nowak, J.F. Baurain, W.P. Mason, H. Wheeler, O.L. Chinot, S. Gill, M. Griffin, L. Rogers, W. Taal, R. Ruda, M. Weller, C. McBainJ. Reijneveld, R.H. Enting, F. Caparrotti, T. Lesimple, S. Clenton, A. Gijtenbeek, E. Lim, U. Herrlinger, P. Hau, F. Dhermain, I. de Heer, K. Aldape, R.B. Jenkins, H.J. Dubbink, J.M. Kros, P. Wesseling, S. Nuyens, V. Golfinopoulos, T. Gorlia, P. French, B.G. Baumert

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Web of Science)
Original languageEnglish
Pages (from-to)813-823
Number of pages11
JournalLancet oncology
Volume22
Issue number6
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • CENTRAL-NERVOUS-SYSTEM
  • OLIGODENDROGLIAL TUMORS
  • EUROPEAN ORGANIZATION
  • IDH2 MUTATIONS
  • PROCARBAZINE
  • VINCRISTINE
  • CLASSIFICATION
  • LOMUSTINE
  • GLIOBLASTOMA
  • PROGRESSION

Cite this